Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of levomilnacipran 75 mg once daily on functional recovery after ischemic stroke
2012-001592-37Phase 3Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke and Post-stroke functional impairment (PSFI) comparing levomilnacipran 75 mg OD with placebo (2 arms). Primary endpoint: Functional recovery response rate at Week 12. Started Jun 2012; status: completed.
02
Drugs
levomilnacipran
03
Conditions
ischemic strokePost-stroke functional impairment (PSFI)
Beyond the preview
Go deeper on 2012-001592-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001592-37.